Skip to search formSkip to main contentSkip to account menu

MI 319

Known as: MI-319, MI319 cpd 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IndolesSpiro Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Inhibition of MDM 2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p 53
Background/Aims: Rapamycin is a potential anti-cancer agent, which modulates the activity of mTOR, a key regulator of cell growth… 
2015
2015
Menin in complex with MI-319
2012
2012
135 The Role of a Novel MicroRNA Cluster, C19MC, in Breast Cancer
2012
2012
Abstract 1021: HDM2 inhibition augments the antitumor and antiangiogenic effects of sunitinib by suppressing sunitinib-induced SDF-1 expression and tumor recruitment of CD11b/Gr1+ MDSC in RCC…
The VEGFR2 inhibitor sunitinib induces transient growth arrest of 786-0 RCC xenografts during which p53 as well as several p53… 
2010
2010
Abstract 381: Enhancement of efficacy of sorafenib and sunitinib with the HDM2 antagonist MI-319 in RCC tumor xenografts
One of the greatest advances in the treatment of renal cell carcinoma (RCC) over the last few years has been the introduction… 
2010
2010
Abstract 4535: MDM2 inhibitor MI-319 in combination with cisplatin/oxaliplatin is an effective treatment for pancreatic cancer independent of p53 function
Pancreatic cancer (PC) is considered to be among the most intractable malignancies as it is refractory to chemotherapy and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)